RADNOR, Pa., Nov. 19, 2018 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting the results of clinical trials of ganaxolone in children with CDKL5 Deficiency Disorder (CDD) and PCDH19-related epilepsy have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in New Orleans on December 2 and 3, 2018.
Details for the poster presentations at the AES Annual Meeting:
“Long-term, Durable Seizure Frequency Reduction in Individuals with CDKL5 Deficiency Disorder (CDD) Treated with Ganaxolone,” N. Specchio, et al.
Abstract #506062. Poster session 3.283
Monday, December 3
8:00 am to 2:00 pm, with authors present from 12:00 Noon to 2:00 PM“Preliminary Evidence of a Predictive Clinical Biomarker in PCDH19-related Epilepsy: Significant Treatment Effect of Ganaxolone In Biomarker-Positive Patients,” J.E. Sullivan, et al.
Abstract # 502507. Poster session 2.251
Sunday, December 2
10:00 am to 4:00 pm, with authors present from 12:00 Noon to 2:00 PM
Marinus is also hosting a Scientific Poster Exhibit on Sunday, December 2. At this exhibit, Marinus’ scientific and medical team will be on-site to discuss ganaxolone and highlight preclinical and clinical data from its clinical development programs in refractory epileptic disorders, including rare genetic epilepsy and status epilepticus.
What: Marinus Pharmaceuticals Scientific Exhibit “Ganaxolone for the Treatment of Refractory Epileptic Disorders”
Where: Room 278-279 (2nd Floor)
When: Sunday, December 2, from 2:00 to 5:00 PM
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus has initiated the first ever pivotal study in children with CDKL5 deficiency disorder, a rare form of epilepsy, and is currently conducting studies in patients with postpartum depression and refractory status epilepticus. For more information visit www.marinuspharma.com. Please follow us on Twitter: @MarinusPharma.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our interpretation of preclinical studies, development plans for our product candidate, including the development of dose forms, the clinical trial testing schedule and milestones, the ability to complete enrollment in our clinical trials, interpretation of scientific basis for ganaxolone use, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, the attainment of clinical trial results that will be supportive of regulatory approvals, and other matters, including the development of formulations of ganaxolone, and the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.
CONTACT:
Lisa M. Caperelli
Executive Director, Investor & Strategic Relations
Marinus Pharmaceuticals, Inc.
484-801-4674
[email protected]
